%0 Journal Article
%T Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability
%A Paul Germonpr¨¦
%A Tim Van den Wyngaert
%J Archive of "PLoS ONE".
%D 2019
%R 10.1371/journal.pone.0215135
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459587/